Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027
Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study
Immutep is narrowing its focus on a drug called efti for two specific cancers. This shows the company is being more selective, which could mean fewer wasted resources but also smaller potential sales.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.